Ipamorelin: The Complete 2026 Guide — The Cleanest GHRP for GH Optimization

If you've spent any time researching growth hormone peptides, you've likely encountered a recurring dilemma: the most potent GHRPs — GHRP-2 and GHRP-6 — come with meaningful hormonal baggage (elevated cortisol, prolactin, and in the case of GHRP-6, ravenous hunger). Ipamorelin was designed to solve exactly that problem.

Discovered in the late 1990s and described in a landmark 1998 paper as the first truly selective growth hormone secretagogue, Ipamorelin delivers robust GH pulses with virtually no effect on cortisol, prolactin, or appetite. That selectivity makes it the preferred GHRP for longer research protocols — and a cornerstone of the most widely prescribed GH peptide stack in clinical practice.

This guide covers everything you need to know: mechanism of action, research-backed benefits, optimal dosing, side effects, comparisons with other GHRPs, and how to use it in stacks.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide (five amino acids) belonging to the growth hormone secretagogue (GHS) class. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH₂. It was developed by Novo Nordisk and characterized in preclinical and clinical research throughout the late 1990s and early 2000s.

Key facts:

• Molecular formula: C₃₈H₄₉N₉O₅
• Molecular weight: 711.9 g/mol
• Half-life: Approximately 2 hours
• Administration: Subcutaneous injection (research use)
• Primary distinction: Selective GH release with no significant cortisol or prolactin elevation

Unlike earlier GHRPs, Ipamorelin was specifically engineered for hormonal selectivity — triggering only the GH axis without the off-target hormonal effects that limit the clinical utility of GHRP-2 and GHRP-6.

Mechanism of Action

Ipamorelin works by binding to the ghrelin receptor (GHS-R1a), the same G-protein coupled receptor targeted by GHRP-2 and GHRP-6. However, the way it activates that receptor — and which downstream signaling cascades it engages — differs in clinically important ways.

Step-by-step mechanism:

1. GHS-R1a binding: Ipamorelin binds selectively to GHS-R1a in pituitary somatotroph cells
2. cAMP elevation: Receptor activation increases cyclic AMP (cAMP), a key second messenger for GH secretion
3. Calcium influx: Intracellular Ca²⁺ rises within somatotrophs, triggering exocytosis of GH vesicles
4. Somatostatin suppression: Like other GHRPs, Ipamorelin blunts somatostatin tone, removing the "brake" on GH release
5. ACTH/cortisol pathway — not activated: Unlike GHRP-2 and GHRP-6, Ipamorelin does not stimulate the hypothalamic-pituitary-adrenal (HPA) axis at any tested dose

The 1998 paper published in the European Journal of Endocrinology (Raun et al.) formally established this selectivity profile: ipamorelin did not elevate ACTH or cortisol at doses up to 200-fold above its GH-releasing ED50. This is qualitatively different from all other known GHRPs, including GHRP-2 and hexarelin.

GH Pulse Characteristics

Ipamorelin produces a discrete, time-limited GH pulse rather than sustained elevation:

• Peak GH: Approximately 40–60 minutes post-injection
• Duration: Returns to baseline within 2–3 hours
• Pattern: Physiologic pulsatile pattern, preserving feedback regulation

This pulsatile pattern mirrors endogenous GH secretion, avoiding the continuous GH elevation associated with exogenous GH therapy and its associated risks.

Benefits of Ipamorelin: What the Research Shows

1. Clean GH Stimulation Without Hormonal Side Effects

This is Ipamorelin's defining advantage. Every other first-generation GHRP — GHRP-2, GHRP-6, Hexarelin — causes measurable elevations in cortisol and/or prolactin alongside GH. Ipamorelin does not.

From a research perspective, this means:

• GH axis effects can be studied in isolation
• Longer protocols are more tolerable
• No catabolic cortisol burden accumulating over time
• No prolactin-mediated suppression of libido or mood

2. Body Composition: Lean Mass and Fat Loss

Elevated GH stimulates IGF-1 production in the liver. IGF-1 drives muscle protein synthesis and satellite cell activation (muscle repair and growth), while GH directly promotes lipolysis (fat mobilization). A 2024 prospective study examining CJC-1295/Ipamorelin in adults aged 40–65 over 12 months found consistent results: 10–15% reductions in visceral fat and modest lean mass gains over the study period.

These findings align with the broader GH secretagogue literature and with the physiological effects of GH elevation more generally.

3. Bone Density and Longitudinal Growth

A 1999 study in Growth Hormone & IGF Research (Svensson et al.) demonstrated that Ipamorelin induced significant longitudinal bone growth in young rats — an effect mediated through GH/IGF-1 axis stimulation. This has implications for research into osteoporosis and age-related bone loss, where GH decline contributes to reduced bone mineral density.

4. Improved Sleep Architecture

GH secretion is tightly coupled to slow-wave (deep) sleep. A randomized, double-blind, placebo-controlled trial published in Sleep Medicine (2025) demonstrated that bedtime administration of CJC-1295/Ipamorelin increased slow-wave sleep duration by 23% (p<0.01). Deeper, more restorative sleep further amplifies GH release in a positive feedback loop.

5. Recovery and Tissue Repair

GH and IGF-1 both play roles in collagen synthesis and tissue repair. Ipamorelin's ability to chronically elevate GH/IGF-1 — without the cortisol burden that would otherwise blunt repair — positions it as a particularly useful tool in recovery-focused research contexts.

6. Anti-Aging and Age-Related GH Decline

Human GH secretion declines approximately 14% per decade after age 30. By age 60, GH output is roughly half of peak young-adult levels. This decline correlates with increases in visceral fat, losses in lean mass, reduced bone density, and declining cognitive function — collectively termed somatopause. Ipamorelin's capacity to restore more youthful GH pulsatility has made it a subject of significant interest in longevity and healthy aging research.

Ipamorelin Dosing Protocols

The following is for educational purposes only. Ipamorelin is a research compound not approved by the FDA for human therapeutic use.

Standard Dosing Parameters

Timing Guidance

• Fasted state is critical: Like all GHRPs, Ipamorelin's GH response is significantly blunted by elevated blood glucose or free fatty acids. Administer at least 2 hours after the last meal, or first thing in the morning.
• Pre-sleep injection: The most commonly used single-dose protocol. Ipamorelin amplifies the natural GH pulse that occurs during slow-wave sleep onset, typically 60–90 minutes after falling asleep.
• Post-exercise injection: Exercise independently elevates GH; Ipamorelin stacks synergistically with this exercise-induced pulse.
• Minimum 3-hour spacing: Between doses, allow GH levels to return to baseline to maintain receptor sensitivity and pulsatility.

Cycle Length and Desensitization

One of Ipamorelin's practical advantages over Hexarelin is its resistance to pituitary desensitization. Hexarelin shows significant receptor downregulation within weeks of continuous use. Ipamorelin maintains efficacy over 16-week research cycles with minimal attenuation of GH response — a property directly related to its selective receptor engagement.

Side Effects of Ipamorelin

Ipamorelin has one of the cleanest side effect profiles of any GH secretagogue. Most adverse effects are mild, dose-dependent, and transient.

Common Side Effects

• Water retention: GH elevation increases sodium and water retention, particularly during the first 2–4 weeks of use. Usually resolves with continued use or dose reduction.
• Injection site reactions: Minor redness, swelling, or discomfort at the subcutaneous injection site. Rotating injection sites minimizes this.
• Headaches: Occasionally reported during the first week, likely related to fluid shifts. Typically transient.
• Mild tingling or numbness: Peripheral tingling (hands, feet) can occur with sustained GH/IGF-1 elevation — the same mechanism as mild carpal tunnel symptoms seen with GH therapy.
• Slight appetite increase: Much milder than GHRP-6. Some researchers report minimal to no change in hunger at standard doses.

What Ipamorelin Does NOT Do (Unlike Other GHRPs)

• Does not significantly elevate cortisol
• Does not significantly elevate prolactin
• Does not significantly stimulate ACTH
• Does not cause pronounced hunger/appetite stimulation
• Does not show rapid pituitary desensitization

These absent effects are not incidental — they are the central pharmacological feature that distinguishes Ipamorelin from the rest of the GHRP class.

Ipamorelin vs GHRP-2 vs GHRP-6: Full Comparison

When to Choose Ipamorelin Over GHRP-2

GHRP-2 produces higher peak GH levels but carries cortisol/prolactin burden. Choose Ipamorelin when:

• Protocol duration exceeds 8 weeks
• Cortisol management is a priority (e.g., research subjects already under physiological stress)
• Appetite suppression is preferred for body composition work
• The clean selectivity of GH axis stimulation is the research objective

Choose GHRP-2 when maximum acute GH output is the priority and the protocol is shorter.

When to Choose Ipamorelin Over GHRP-6

GHRP-6 is uniquely suited to research involving appetite and weight gain (e.g., cachexia models). Outside of that niche, Ipamorelin is superior: higher potency, no hunger signal, and the same absence of cortisol/prolactin effects.

Ipamorelin + CJC-1295: The Gold Standard Stack

CJC-1295 + Ipamorelin is the most widely prescribed GH peptide combination in clinical settings — and for good reason. The two peptides target completely different receptors and create genuine synergy:

• CJC-1295 (GHRH analog) binds the GHRH receptor, increases pituitary GH content, and primes somatotrophs for larger secretory events
• Ipamorelin (GHS-R1a agonist) triggers the actual GH pulse while simultaneously suppressing somatostatin

The result: GH pulses that can be 2–10x larger than either compound alone, while maintaining Ipamorelin's clean side effect profile. CJC-1295 does not alter Ipamorelin's hormonal selectivity — the stack does not introduce cortisol or prolactin elevation.

Standard CJC-1295 + Ipamorelin Stack

CJC-1295 without DAC (Modified GRF 1-29) is preferred for this stack. Its short half-life (~30 minutes) aligns precisely with Ipamorelin's pulse timing, creating a coordinated dual-signal burst. CJC-1295 with DAC has a multi-day half-life, creating a tonic GH bleed rather than discrete pulses — appropriate for some protocols but not ideal for maximizing peak GH with Ipamorelin.

Single-Dose Bedtime Protocol (Most Common)

For simplicity and sleep optimization, many research protocols use a single nightly injection:

• CJC-1295 (no DAC): 100 mcg + Ipamorelin: 200–300 mcg
• Administered 30–60 minutes before sleep in a fasted state
• This amplifies the natural early-sleep GH pulse maximally

Reconstitution and Storage

Ipamorelin is supplied as a lyophilized (freeze-dried) powder:

1. Reconstitute with bacteriostatic water (BW) — the preservative extends usable life
2. Add BW slowly down the vial wall; do not inject directly onto the powder
3. Swirl gently — never shake (shaking can denature peptide bonds)
4. Reconstituted Ipamorelin: refrigerate at 2–8°C, use within 30 days
5. Lyophilized powder: store at -20°C; stable for 12–24 months when kept frozen and dry

Tip: When stacking with CJC-1295, both peptides can be drawn into the same syringe immediately before injection. Do not mix reconstituted peptides and store together — draw and inject same-session only.

Legal and Regulatory Status

Ipamorelin is not FDA-approved for human therapeutic use in the United States. It is classified as a research compound. It is prohibited by WADA in competitive sport.

In the United States, CJC-1295 and Ipamorelin were historically available through 503A compounding pharmacies under physician supervision. The FDA's 2023 and 2024 actions significantly restricted compounded peptide availability, placing many peptides including Ipamorelin on lists of compounds not eligible for compounding. The regulatory landscape continues to evolve — consult current FDA guidance and a licensed healthcare provider for the most up-to-date status.

Who Is Ipamorelin Research Most Relevant For?

Based on the published literature, Ipamorelin research is most applicable to:

• Age-related GH decline (somatopause): Adults 35+ experiencing declining GH output, with associated changes in body composition, sleep quality, and bone density
• Long-duration GH optimization protocols: Where cortisol burden from GHRP-2/Hexarelin would be problematic over 12+ weeks
• Sleep and recovery research: Given the documented slow-wave sleep enhancement
• Body composition research: Where appetite control is important alongside GH elevation
• Basic selectivity research: Ipamorelin's defined pharmacological profile makes it a useful tool for isolating GH axis effects from ACTH/cortisol pathway activation

Conclusion

Ipamorelin earns its title as the first — and still most defining — selective growth hormone secretagogue. Where GHRP-2 offers brute GH output and GHRP-6 drives appetite, Ipamorelin offers something more nuanced and clinically useful: reliable, pulsatile GH release with a side effect profile clean enough to support extended research protocols.

Its synergy with CJC-1295 has made the combination the dominant clinical GH peptide stack — adopted in longevity medicine, sports medicine, and weight management contexts where GH optimization is the goal and hormonal selectivity matters. For researchers studying GH secretagogues, Ipamorelin remains the benchmark for what a selective GH-releasing peptide should look like.

Disclaimer: This article is for educational purposes only. Ipamorelin is a research compound not approved by the FDA for human use. Nothing in this article constitutes medical advice. Always consult a licensed healthcare provider before using any peptide or hormone-related compound.